Bliss GVS Pharma Board Approves Two New ESOP Schemes
Bliss GVS Pharma Ltd 路 Outcome 路 02 Oct 2026, 1:16 am
Bliss GVS Pharma Board Approves Two New ESOP Schemes Bliss GVS Pharma鈥檚 board approved the adoption of the Senior Executive ESOP 2026 and Employee ESOP 2026 on 1st Oct'26, subject to shareholder approval. The Senior Executive ESOP 2026 covers up to 26,50,000 equity shares (~2.49% of paid-up equity), while the Employee ESOP 2026 covers up to 47,00,000 equity shares (~4.42% of paid-up equity) on a fully diluted basis. Both schemes carry a fixed discounted exercise price of INR 10 per share with a minimum one-year vesting period.
Original exchange filing (PDF)
More announcements from Bliss GVS Pharma Ltd
- Please find enclosed herewith the Intimation under Regulation 30 of the SEBI Listing Regulations. 路 06 Nov 2026
- We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products .... 路 04 Nov 2026
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 29 Oct 2026
- Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss .... 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. 路 29 Oct 2026
- Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 29 Oct 2026
